The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030

January 6, 2021

The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030


Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.


To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link


Key Market Insightsh

  • An analysis of recent activity on Twitter confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality
  • About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts
  • The pipeline features both small molecules and biologic drugs based on different synlet targets for treating a variety of oncological and non-oncological indications
  • Innovation in this domain is evident across the plethora of scientific articles published in prestigious journals, highlighting key focus areas and prevalent / upcoming trends
  • Over time, several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on the identification of novel synlet targets across different clinical conditions
  • Significant advances in research have led to the discovery of a wide array of synlet targets; over time, substantial intellectual capital has been generated and validated by eminent scientists from renowned research institutes
  • To support innovation, several private and public investors have made substantial capital investments, totalling to approximately USD 5.1 billion, across 100 instances of funding
  • The personalized approach offered by companion diagnostics presents enormous opportunities for drug developers to partner with diagnostic test providers to improve patient / subject selection in clinical trials
  • Future growth of the market is likely to be driven by the success of clinical outcomes of late-stage molecules; industry stakeholders are optimistic about the vast potential of PARP inhibitors
  • In the mid to long term, the anticipated market opportunity is likely to be well distributed across advanced cancer indications, delivery routes and various global regions


For more information, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Article Categories:

Leave a Comment